NewAmsterdam Pharma Company (NAMS) Stock Forecast, Price Target & Predictions
NAMS Stock Forecast
NewAmsterdam Pharma Company stock forecast is as follows: an average price target of $36.50 (represents a 82.41% upside from NAMS’s last price of $20.01) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
NAMS Price Target
The average price target for NewAmsterdam Pharma Company (NAMS) is $36.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $37.00 to $36.00. This represents a potential 82.41% upside from NAMS's last price of $20.01.
NAMS Analyst Ratings
According to 3 Wall Street analysts, NewAmsterdam Pharma Company's rating consensus is 'Buy'. The analyst rating breakdown for NAMS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
NewAmsterdam Pharma Company Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Yasmeen Rahimi | Piper Sandler | $37.00 | $15.95 | 131.97% | 84.91% |
| Aug 28, 2024 | Serge Belanger | Needham | $36.00 | $16.77 | 114.67% | 79.91% |
The latest NewAmsterdam Pharma Company stock forecast, released on Sep 23, 2024 by Yasmeen Rahimi from Piper Sandler, set a price target of $37.00, which represents a 131.97% increase from the stock price at the time of the forecast ($15.95), and a 84.91% increase from NAMS last price ($20.01).
NewAmsterdam Pharma Company Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 2 |
| Avg Price Target | - | $36.50 | $36.50 |
| Last Closing Price | $20.01 | $20.01 | $20.01 |
| Upside/Downside | -100.00% | 82.41% | 82.41% |
In the current month, the average price target of NewAmsterdam Pharma Company stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NewAmsterdam Pharma Company's last price of $20.01. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 21, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 23, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Sep 23, 2024 | RBC Capital | Buy | Buy | Hold |
| Sep 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 28, 2024 | Needham | Buy | Mixed | Initialise |
| Aug 28, 2024 | Needham | - | Buy | Initialise |
| Aug 27, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 15, 2024 | Cowen & Co. | - | Buy | Initialise |
NewAmsterdam Pharma Company's last stock rating was published by Piper Sandler on Oct 21, 2024. The company gave NAMS a "Overweight" rating, the same as its previous rate.
NewAmsterdam Pharma Company Financial Forecast
NewAmsterdam Pharma Company Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $1.26M | $900.85K | $540.50K | $270.25K | $19.01M | $20.70M | $22.54M | $24.55M | $1.72M | $1.87M | $1.21M | $1.62M | $2.89M |
| High Forecast | $1.88M | $1.35M | $807.33K | $403.66K | $28.39M | $30.92M | $33.67M | $36.67M | $2.57M | $1.89M | $1.25M | $1.66M | $3.12M |
| Low Forecast | $638.56K | $456.13K | $273.67K | $136.84K | $9.62M | $10.48M | $11.41M | $12.43M | $872.01K | $1.85M | $1.16M | $1.57M | $2.65M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 4 | 1 | 1 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
NewAmsterdam Pharma Company's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NAMS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
NewAmsterdam Pharma Company EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 4 | 1 | 1 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $304.39K | $217.43K | $130.46K | $65.23K | $4.59M | $5.00M | $5.44M | $5.92M | $415.68K | $451.84K | $291.09K | $390.74K | $696.73K |
| High Forecast | $454.67K | $324.77K | $194.86K | $97.43K | $6.85M | $7.46M | $8.13M | $8.85M | $620.89K | $457.02K | $301.02K | $401.43K | $752.03K |
| Low Forecast | $154.12K | $110.09K | $66.05K | $33.03K | $2.32M | $2.53M | $2.75M | $3.00M | $210.47K | $446.65K | $281.16K | $380.05K | $639.22K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict NAMS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than NewAmsterdam Pharma Company's previous annual EBITDA (undefined) of $NaN.
NewAmsterdam Pharma Company Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 4 | 1 | 1 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-41.38M | $-39.19M | $-37.10M | $-36.43M | $-39.73M | $-40.48M | $-42.03M | $-42.28M | $-44.86M | $-42.35M | $-50.93M | $-54.48M | $-50.36M |
| High Forecast | $-14.83M | $-14.04M | $-13.29M | $-13.05M | $-14.23M | $-14.50M | $-15.06M | $-39.64M | $-41.27M | $-15.17M | $-18.24M | $-19.52M | $-46.02M |
| Low Forecast | $-67.94M | $-64.33M | $-60.91M | $-59.81M | $-65.23M | $-66.47M | $-69.01M | $-44.92M | $-47.55M | $-69.53M | $-83.61M | $-89.45M | $-58.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
NewAmsterdam Pharma Company's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NAMS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
NewAmsterdam Pharma Company SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 4 | 1 | 1 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $1.43M | $1.02M | $611.12K | $305.56K | $21.49M | $23.40M | $25.49M | $27.75M | $1.95M | $2.12M | $1.36M | $1.83M | $3.26M |
| High Forecast | $2.13M | $1.52M | $912.81K | $456.40K | $32.10M | $34.96M | $38.07M | $41.46M | $2.91M | $2.14M | $1.41M | $1.88M | $3.52M |
| Low Forecast | $721.98K | $515.72K | $309.43K | $154.71K | $10.88M | $11.85M | $12.90M | $14.05M | $985.94K | $2.09M | $1.32M | $1.78M | $2.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
NewAmsterdam Pharma Company's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NAMS last annual SG&A of $NaN (undefined).
NewAmsterdam Pharma Company EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 4 | 1 | 1 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.44 | $-0.41 | $-0.39 | $-0.38 | $-0.42 | $-0.43 | $-0.44 | $-0.45 | $-0.47 | $-0.45 | $-0.54 | $-0.57 | $-0.53 |
| High Forecast | $-0.16 | $-0.15 | $-0.14 | $-0.14 | $-0.15 | $-0.15 | $-0.16 | $-0.42 | $-0.44 | $-0.16 | $-0.19 | $-0.21 | $-0.49 |
| Low Forecast | $-0.72 | $-0.68 | $-0.64 | $-0.63 | $-0.69 | $-0.70 | $-0.73 | $-0.47 | $-0.50 | $-0.73 | $-0.88 | $-0.94 | $-0.61 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, NewAmsterdam Pharma Company's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NAMS previous annual EPS of $NaN (undefined).
NewAmsterdam Pharma Company Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IVA | Inventiva | $2.74 | $36.00 | 1213.87% | Buy |
| PEPG | PepGen | $4.40 | $29.50 | 570.45% | Buy |
| MOLN | Molecular Partners | $5.20 | $29.00 | 457.69% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| CMPX | Compass Therapeutics | $1.37 | $5.00 | 264.96% | Buy |
| RZLT | Rezolute | $5.01 | $13.50 | 169.46% | Buy |
| PRTC | PureTech Health | $21.70 | $57.00 | 162.67% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| CGEM | Cullinan Oncology | $12.58 | $31.50 | 150.40% | Buy |
| MLYS | Mineralys Therapeutics | $12.60 | $30.00 | 138.10% | Buy |
| REPL | Replimune Group | $11.23 | $24.20 | 115.49% | Buy |
| NAMS | NewAmsterdam Pharma Company | $20.01 | $36.50 | 82.41% | Buy |
| MRUS | Merus | $42.93 | $77.13 | 79.66% | Buy |
| CRNX | Crinetics Pharmaceuticals | $56.07 | $70.14 | 25.09% | Buy |
| JANX | Janux Therapeutics | $48.96 | $61.20 | 25.00% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |